Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting



Status:Recruiting
Conditions:High Blood Pressure (Hypertension), Ocular
Therapuetic Areas:Cardiology / Vascular Diseases, Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:3/24/2019
Start Date:December 27, 2018
End Date:September 2019
Contact:Julia Williams
Email:jmwilliams@aeriepharma.com
Phone:949-526-8731

Use our guide to learn which trials are right for you!

A Multicenter, Open-label Study of Rhopressa® (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as
monotherapy or when used concomitantly with other IOP-lowering agents in subjects with
elevated IOP due to open angle glaucoma or ocular hypertension in a real-world clinical
setting. The study is an open-label design. The patients will receive treatment for 12 weeks.


Key Inclusion Criteria:

1. Male or female subjects (aged 18 or older)

2. Subjects diagnosed with open-angle glaucoma or ocular hypertension, and determined by
the treating physician to require additional intraocular pressure (IOP)-lowering
treatment with netarsudil 0.02%.

3. Willingness to follow protocol requirements, including signed informed consent,
routine follow-up schedule, completing questionnaires and completing laboratory tests

Key Exclusion Criteria:

1. Have any active ocular disease other than glaucoma or ocular hypertension that would
interfere with study interpretation

2. Women of childbearing potential who are pregnant, nursing, or planning a pregnancy and
not using a medically acceptable form of birth control. Male subjects with a female
partner of childbearing potential must have had a prior vasectomy or agree to use an
effective method of birth control during the treatment period and for 3 months after
the subject has completed the study.

3. Known sensitivity or allergy to the study medication or components

4. Any systemic disease or clinical evidence of any condition which would make the
subject, in the opinion of the investigator, unsuitable for the study or could
potentially confound the study results

5. Concurrent participation or prior participation in any investigational drug or device
study within the last 30 days prior to the Baseline Visit
We found this trial at
17
sites
Nashville, Tennessee 37204
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Austin, Texas 78731
?
mi
from
Austin, TX
Click here to add this to my saved trials
Baltimore, Maryland 21204
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
El Paso, Texas 79902
?
mi
from
El Paso, TX
Click here to add this to my saved trials
Houston, Texas 77025
?
mi
from
Houston, TX
Click here to add this to my saved trials
Huntingdon Valley, Pennsylvania 19006
?
mi
from
Huntingdon Valley, PA
Click here to add this to my saved trials
137 Gateway Drive
Ladson, South Carolina 29456
?
mi
from
Ladson, SC
Click here to add this to my saved trials
Laguna Hills, California 92653
?
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Memphis, Tennessee
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Memphis, Tennessee 38120
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Petaluma, California 94954
?
mi
from
Petaluma, CA
Click here to add this to my saved trials
Racine, Wisconsin 53405
?
mi
from
Racine, WI
Click here to add this to my saved trials
Roswell, Georgia 30076
?
mi
from
Roswell, GA
Click here to add this to my saved trials
9911 Kennerly Road
Saint Louis, Missouri 63128
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Sarasota, Florida 34239
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Tulsa, Oklahoma 74104
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Wheaton, Illinois 60187
?
mi
from
Wheaton, IL
Click here to add this to my saved trials